A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P4502C9

被引:126
作者
Tham, Lai-San
Goh, Boon-Cher
Nafziger, Anne
Guo, Jia-Yi
Wang, Ling-Zhi
Soong, Richie
Lee, Soo-Chin
机构
[1] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore 119074, Singapore
[2] Oncol Res Inst, Singapore, Singapore
[3] Ordway Res Inst, Drug Dev Ctr, Albany, NY USA
关键词
D O I
10.1016/j.clpt.2006.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Because of the unique lack of genetic diversity despite the multiethnicity in the Asian population, we hypothesize that single-nucleotide polymorphisms in cytochrome P450 (CYP) 2C9 (CYP2C9*3) and vitamin Kepoxide reductase complex subunit 1 (VKORC1) at position 381, used to infer VKORC1 haplotype in combination with demographic factors, can accurately predict warfarin doses. The aims of this study were to derive a pharmacogenetics-based dosing algorithm by use of retrospective information and to validate it through a data-splitting method in a separate cohort of equal size. Methods. We used 215 records of warfarin patients recruited into a CYP2C9/VKORC1 genotyping study to perform this analysis. Univariate analyses for individual predictors, including age, weight, gender, serum albumin concentration, ethnic group, international normalized ratio, and CYP2C9 and VKORC1 381 genotypes, were conducted to select variables with P < .1 for further inclusion into the multivariate regression analysis. In the final model only predictors reaching a statistical significance of P < .05 were retained. Results. Data from 107 subjects undergoing maintenance warfarin therapy with an international normalized ratio stabilized between 2 and 3 were used to derive the final model, as an exponential function of age, weight, CYP2C9*3 allele, and VKORC1 381 CC and TC genotypes, and this model accounted for 60.2% of the variability in daily warfarin dose requirement. The model was validated in a separate cohort of 108 subjects and showed a mean underestimation of 0.23 +/- 1.21 mg/d. Conclusion: Warfarin dose requirements in Asians can be accurately predicted by use of a combination of patient demographics and a simplified genotyping approach for single variants in CYP2C9 and VKORC1.
引用
收藏
页码:346 / 355
页数:10
相关论文
共 41 条
  • [1] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
    Aquilante, CL
    Langaee, TY
    Lopez, LM
    Yarandi, HN
    Tromberg, JS
    Mohuczy, D
    Gaston, KL
    Waddell, CD
    Chirico, MJ
    Johnson, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 291 - 302
  • [2] Allele and genotype frequencies of CYP2C9 in a Korean population
    Bae, JW
    Kim, HK
    Kim, JH
    Yang, SI
    Kim, MJ
    Jang, CG
    Park, YS
    Lee, SY
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 418 - 422
  • [3] CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
    Chern, HD
    Ueng, TH
    Fu, YP
    Cheng, CW
    [J]. CLINICA CHIMICA ACTA, 2006, 367 (1-2) : 108 - 113
  • [4] A randomized trial comparing 5-mg and 10-mg warfarin loading doses
    Crowther, MA
    Ginsberg, JB
    Kearon, C
    Harrison, L
    Johnson, J
    Massicotte, P
    Hirsh, J
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) : 46 - 48
  • [5] FLEXIBLE INDUCTION DOSE REGIMEN FOR WARFARIN AND PREDICTION OF MAINTENANCE DOSE
    FENNERTY, A
    DOLBEN, J
    THOMAS, P
    BACKHOUSE, G
    BENTLEY, DP
    CAMPBELL, IA
    ROUTLEDGE, PA
    [J]. BRITISH MEDICAL JOURNAL, 1984, 288 (6426) : 1268 - 1270
  • [6] Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
    Furuya, H
    FernandezSalguero, P
    Gregory, W
    Taber, H
    Steward, A
    Gonzalez, FJ
    Idle, JR
    [J]. PHARMACOGENETICS, 1995, 5 (06): : 389 - 392
  • [7] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Gage, BF
    Eby, C
    Milligan, PE
    Banet, GA
    Duncan, JR
    McLeod, HL
    [J]. THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) : 87 - 94
  • [8] A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients
    Gedge, J
    Orme, S
    Hampton, KK
    Channer, KS
    Hendra, TJ
    [J]. AGE AND AGEING, 2000, 29 (01) : 31 - 34
  • [9] CONTROL OF NORWAY RATS WITH RESIDUAL RODENTICIDE WARFARIN
    HAYES, WJ
    GAINES, TB
    [J]. PUBLIC HEALTH REPORTS, 1950, 65 (47) : 1537 - 1555
  • [10] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    Higashi, MK
    Veenstra, DL
    Kondo, LML
    Wittkowsky, AK
    Srinouanprachanh, SL
    Farin, FM
    Rettie, AE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1690 - 1698